Julie E. Weiss

Julie E. Weiss

Auto-generated profile, based on publicly available information

Julie E. Weiss

Dartmouth Cancer Center, Lebanon, New Hampshire

Research Focus & Metrics

Academic Career Length

32Years (1995-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 1995 in Anesthesiology
Verified
Journal Article
Open access
PDF file
MYMark P. Yeager
Mark P. Yeager
TCThomas A. Colacchio
Thomas A. Colacchio
CYCecelia T. Yu
Cecelia T. Yu
LHLaurie Hildebrandt
Laurie Hildebrandt
AHAlexandra L. Howell
Alexandra L. Howell
PGPaul M. Guyre
Paul M. Guyre
Background: Opioids are used by patients who have conditions ranging from the acute pain of surgery and chronic cancer pain to substance abuse. Despite their widespread use and considerable experimental data about them, little is known about how opioids may alter in vivo immunity in humans. This study was designed to evaluate the in vivo effect of morphine on human peripheral blood immune functions. Methods: Healthy volunteers underwent continuous exposure to morphine for 36 h including a 24-h intravenous infusion in the hospital. Peripheral blood was drawn for immune function studies at five measurement times before, during, and after morphine exposure. Peripheral blood mononuclear cells were tested for acute and gamma-interferon-stimulated natural killer cell cytotoxicity (NKCC), antibody-dependent cell cytotoxicity, antibody Fc receptor expression, and human immunodeficiency virus infectivity. Results: Significant suppression of NKCC was observed at 2 and 24 h after the onset of intravenous morphine exposure. Suppression of NKCC persisted for 24 h after termination of morphine infusion in a "high"-dose study group. gamma-Interferon-stimulated NKCC and antibody-dependent cell cytotoxicity were also decreased after 24 h of intravenous morphine exposure. No effect on Fc receptor expression was observed. Mean virus antigen production after lymphocyte infection with human immunodeficiency virus was not increased (p24 100 ng/ml after morphine vs. 43 ng/ml before morphine; P = 0.17). Conclusions: These results suggest that morphine administration, at doses within the range of analgesic use, can cause measurable suppression of some components of the human cellular immune system.

18 December 1996 in JNCI: Journal of the National Cancer Institute
Verified
Journal Article
Open access
PDF file
MKM R Karagas
M R Karagas
JMJ A McDonald
J A McDonald
EGE R Greenberg
E R Greenberg
TST A Stukel
T A Stukel
JWJ E Weiss
J E Weiss
MSM M Stevens
M M Stevens
Human evidence that ionizing radiation is carcinogenic first came from reports of nonmelanoma skin cancers (NMSCs) on the hands of workers using early radiation devices. An increased risk of NMSC has been observed among uranium miners, radiologists, and individuals treated with x rays in childhood for tinea capitis (ringworm of the scalp) or for thymic enlargement; NMSC is one of the cancers most strongly associated with the atomic bombing of Hiroshinma and Nagasaki. Although exposure to ionizing radiation is a known cause of NMSC, it is not yet clear whether therapeutic radiation causes both major histologic types of NMSC, basal cell carcinoma (BCC) and squamous cell carcinomas (SCC). Additionally, the potentially modifying effects, such as latency, age when treated, and type of treatment, are not well understood. We investigated the relative risks of BCC and SCC associated with previous radiation therapy and evaluated these risks in relation to age and time since initial treatment and the medical condition for which radiation therapy was given. The study group comprised individuals diagnosed with at least one BCC or SCC from January 1980 through February 1986, who were recruited to participate in a skin cancer prevention trial designed to test whether oral βcarotene supplementation would reduce the risk of new NMSCs. Patients were identified through the dermatology and pathology records of academic medical centers in Hanover, NH; Los Angeles, CA; San Francisco, CA; and Minneapolis, MN. Each participant completed a questionnaire detailing lifetime residence, pigmentary characteristics, occupational and recreational sun exposure, and history of radiation therapy. At enrollment, a study dermatologist assessed skin type (tendency to burn or tan) and extent of actinic skin damage. Participants were followed with an annual dermatologic examination for an average of 4 years. Of the 5232 potentially eligible individuals, 1805 were enrolled in the trial. We excluded 112 patients who reported previous radiation therapy for skin cancer only and three with missing information on whether they were ever treated with radiation therapy, leaving 1690 patients for the analysis. Approximately 4% of the patients died or discontinued participation for other reasons during each study year. We examined time to occurrence of first new histopathologically confirmed BCC and SCC during the follow-up period in relation to history of radiation therapy (for reasons other than NMSC) using a proportional hazards model. A multiple end points survival model was used to compare the rate ratios (RRs) for BCC and SCC. We also used a longitudinal method of analysis to compute the RR of total new BCC and SCC tumors per person per study year associated with radiation therapy. Using this method, we additionally assessed the potential modifying effects of age at treatment, latency, and type of therapy. All P values were derived from two-sided statistical tests of significance. Among the participants we studied, 597 developed a new BCC (n = 1553 tumors) and 118 developed a new SCC (n= 179 tumors). The time to first new BCC, but not SCC, was associated with prior radiation therapy (RR = 1.7; 95% confidence interval [CI] = 1.4−2.0 and RR = 1.0; 95% CI=0.6−1.7, respectively; P =.03 for the difference between the RRs). The RR of total BCC tumors was slightly higher(RR = 23; 95% CI=1.7−3.1), but it was still unity for SCC (RR=1.0; 95% CI=0.5−1.9). BCC risk appeared to increase with younger age at exposure and time since initally treated, although these effects were only marginally statistically significant (P for trend =.06 and.07, respectively). Also, risk of BCC was more strongly related to treatment for acne (RR = 33; 95% CI = 2.1–5.2) than other conditions. Our data suggest that exposure to therapeutic radiation is associated with BCC but not with SCC. Several aspects of the relationship of ionizing radiation exposure to the risk for skin cancer are not yet fully understood and warrant continued investigation. [J Natl Cancer Inst 1996;88:1848−53]

1 March 2014 in American Journal of Gastroenterology
Verified
Journal Article
Closed access
LBLynn Butterly
Lynn Butterly
CRChristina M Robinson
Christina M Robinson
JAJoseph C Anderson
Joseph C Anderson
JWJulia E Weiss
Julia E Weiss
MGMartha Goodrich
Martha Goodrich
MBMichael L Beach
Michael L Beach
L time as a quality indicator remains controversial. Few studies have reported on withdrawal time and serrated polyp detection. Using data from the New Hampshire Colonoscopy Registry, we examined how an endoscopist's withdrawal time in normal colonoscopies affects adenoma and serrated polyp detection. METHODS: We analyzed 7,996 colonoscopies performed in 7,972 patients between 2009 and 2011 by 42 endoscopists at 14 hospitals, ambulatory surgery centers, and community practices. CSSPs were defined as sessile serrated polyps and hyperplastic polyps proximal to the sigmoid. Adenoma and CSSP detection rates were calculated based on median endoscopist withdrawal time in normal exams. Regression models were used to estimate the association of increased normal withdrawal time and polyp, adenoma, and CSSP detection. RESULTS: Polyp and adenoma detection rates were highest among endoscopists with 9 min median normal withdrawal time, and detection of CSSPs reached its highest levels at 8–9 min. Incident rate ratios for adenoma and CSSP detection increased with each minute of normal withdrawal time above 6 min, with maximum benefit at 9 min for adenomas (1.50, 95% confidence interval (CI) (1.21, 1.85)) and CSSPs (1.77, 95% CI (1.15, 2.72)). When modeling was used to set the minimum withdrawal time at 9 min, we predicted that adenomas and CSSPs would be detected in 302 (3.8%) and 191 (2.4%) more patients. The increase in detection was most striking for the CSSPs, with nearly a 30% relative increase. CONCLUSIONS: A withdrawal time of 9 min resulted in a statistically significant increase in adenoma and serrated polyp detection. Colonoscopy quality may improve with a median normal withdrawal time benchmark of 9 min....

1 July 2000 in American Journal of Epidemiology
Verified
Journal Article
Open access
MKMargaret R. Karagas
Margaret R. Karagas
TTTor D. Tosteson
Tor D. Tosteson
JBJoel Blum
Joel Blum
BKBjoern Klaue
Bjoern Klaue
JWJulia E. Weiss
Julia E. Weiss
JMJ. Steven Morris
J. Steven Morris
A study was conducted to evaluate toenail arsenic concentrations as a biologic marker of drinking water arsenic exposure. Study subjects were controls in a US population-based case-control study of nonmelanoma skin cancer, randomly selected from drivers' license records (those <65 years of age) and Medicare enrollment files (those ≥65 years of age). Between 1994 and 1997, a total of 540 controls were interviewed and toenail samples of sufficient weight were collected from 506 (93.7%) of these. Beginning in 1995, a sample of tap water was taken from the participants' homes; a total of 217 (98.6%) water samples were obtained from the 220 subjects interviewed. Arsenic determinations were made from toenail samples using neutron activation analysis. Water samples were analyzed using hydride-generation magnet sector inductively coupled mass spectrometry. Among 208 subjects with both toenail and water measurements, the correlation (r) between water and nail arsenic was 0.65 (p < 0.001) among those with water arsenic concentrations of 1 μg/liter or higher and 0.08 (p = 0.31) among those with concentrations below 1 μg/liter (overall r = 0.46, p < 0.001). Our data suggest that toenail samples provide a useful biologic marker for quantifying low-level arsenic exposure.

15 March 2001 in American Journal of Epidemiology
Verified
Journal Article
Open access
PDF file
MKMargaret R. Karagas
Margaret R. Karagas
TSTherese A. Stukel
Therese A. Stukel
JMJ. Steven Morris
J. Steven Morris
TTTor D. Tosteson
Tor D. Tosteson
JWJulia E. Weiss
Julia E. Weiss
EGE. Robert Greenberg
E. Robert Greenberg
Arsenic is a known carcinogen specifically linked to skin cancer occurrence in regions with highly contaminated drinking water or in individuals who took arsenic-containing medicines. Presently, it is unknown whether such effects occur at environmental levels found in the United States. To address this question, the authors used data collected on 587 basal cell and 284 squamous cell skin cancer cases and 524 controls interviewed as part of a case-control study conducted in New Hampshire between 1993 and 1996. Arsenic was determined in toenail clippings using instrumental neutron activation analysis. The odds ratios for squamous cell carcinoma (SCC) and basal cell carcinoma (BCC) were close to unity in all but the highest category. Among individuals with toenail arsenic concentrations above the 97th percentile, the adjusted odds ratios were 2.07 (95% confidence interval (CI): 0.92, 4.66) for SCC and 1.44 (95% CI: 0.74, 2.81) for BCC, compared with those with concentrations at or below the median. While the risks of SCC and BCC did not appear elevated at the toenail arsenic concentrations detected in most study subjects, the authors cannot exclude the possibility of a dose-related increase at the highest levels of exposure experienced in the New Hampshire population.

1 June 2017 in Gastrointestinal Endoscopy
Verified
Journal Article
Closed access
JAJoseph C. Anderson
Joseph C. Anderson
LBLynn F. Butterly
Lynn F. Butterly
JWJulia E. Weiss
Julia E. Weiss
CRChristina M. Robinson
Christina M. Robinson